Gastrointestinal Stromal Tumors Treated by Mesylate Imatinib to the Teaching Hospital of Brazzaville

Context: The significant advanced into the comprehension of some mechanism of carcinogenesis of GIST and, thanks to the program GIPAP (Glivec International Patient Assistance Program); our patients should benefit from the minimum standard fare gratuitously of the mesylate imatinib treatment since 2008. Objectives: To evaluate the treatment of patients followed by GIST imatinib mesylate into the Service of Carcinology and Radiotherapy of Brazzaville Teaching Hospital. Materials and Methods: It was done a descriptive study with retrospective incorporating 11 cases over a 66 months period from 1st January 2010 to 30th June 2015. Patients were treated with a combination of surgery and targeted therapy (imatinib mesylate 100 mg 2cp x 2/day) or exclusively by targeted therapy. Overall survival was calculated by the Actuarial method